Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

20062,733 citationsJournal Articlebronze Open Access

Authors

Ajay Singh · Harvard University

Lynda A. Szczech · Clinical Research Institute

Kezhen L. Tang · Ortho Clinical Diagnostics (United States)

Huiman X. Barnhart · Duke University

Shelly Sapp · Clinical Research Institute

Marsha Wolfson · Ortho Clinical Diagnostics (United States)

Donal Reddan

Abstract

The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter) was associated with increased risk and no incremental improvement in the quality of life. (ClinicalTrials.gov number, NCT00211120 [ClinicalTrials.gov].).

Topics & Keywords

Erythropoietin and Anemia Treatment Iron Metabolism and Disorders Hemoglobinopathies and Related Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 20, pp. 2085-2098

DOI: 10.1056/nejmoa065485

Field-Weighted Citation Impact: 94.94